[ad_1]
NEW YORK, May 16, 2022 /PRNewswire/ — The “Anticoagulant Reversal Drugs Market“ report has been added to Technavio’s offering. The potential growth difference for the anticoagulant reversal drugs market from 2021 to 2026 is USD 877.37 million. To get the exact yearly growth variance and the YOY growth rate, Download Sample Report.
Key Market Dynamics:
- Market Driver
- Market Challenges
The rising frequency of coagulation diseases such as Von Willebrand disease, hemophilia, deep venous thrombosis, hypercoagulable states, and clotting factor deficiencies is one of the primary reasons driving the worldwide anticoagulant reversal medicines market growth. However, factors such as product recalls will challenge market growth.
To learn about additional key drivers, trends, and challenges available with Technavio. Read our Sample Report right now!
Key Market Segmentation
The anticoagulant reversal drugs market report is segmented by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Geography (North America, Europe, Asiaand the Rest of the World (ROW)). North America will be the leading region with 43% of the market’s growth during the forecast period. The US, CanadaUK, Germany, Franceand China are the key market for anticoagulant reversal drugs in North America.
The hospital pharmacy sector will gain a considerable proportion of the anticoagulant reversal medicines market. This increase is due to an increase in the number of people being admitted to hospitals for serious illnesses or for basic monitoring after procedures, causing hospitals to boost their investments in hospital pharmacies.
View our sample report for additional insights into the contribution of all the segments, and regional opportunities in the report.
Some Companies Mentioned with their Offerings
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
- Amboss GmbH
- Amneal Pharmaceuticals Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Boehringer Ingelheim International GmbH
- Covis Pharma BV
- CSL Ltd.
- GoodRx Holdings Inc.
- Midas Pharma GmbH
- Pfizer Inc.
To gain access to more vendor profiles with their key offerings available with Technavio, Click Here
Geographical Market Analysis
North America will account for 43 percent of market growth. In North Americaanticoagulant reversal medicines are mostly sold in the United States and Canada. The market in this region will increase at a quicker rate than the market in other regions.
Over the forecast period, the availability of direct reimbursement policies and contemporary healthcare infrastructure will aid the expansion of the anticoagulant reversal medicines market in North America.
Know more about this market’s geographical distribution along with a detailed analysis of the top regions. Download Sample Report.
Customize Your Report
Don’t miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.
Do reach out to our analysts for more customized reports as per your requirements. Speak to our Analyst now!
Related Reports:
Topical Drugs Market by Product and Geography – Forecast and Analysis 2022-2026
|
Anticoagulant Reversal Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 12.27% |
|
Market growth 2022-2026 |
$877.37 million |
|
Market structure |
Fragmented |
|
YoY growth (%) |
12.0 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 43% |
|
Key consumer countries |
US, Canada, UK, Germany, France, and China |
|
| |
Full story available on Benzinga.com
[ad_2]
Source link
